<?xml version='1.0' encoding='utf-8'?>
<document id="23887590"><sentence text="Effect of Ritonavir on (99m)Technetium-Mebrofenin Disposition in Humans: A Semi-PBPK Modeling and In Vitro Approach to Predict Transporter-Mediated DDIs."><entity charOffset="10-19" id="DDI-PubMed.23887590.s1.e0" text="Ritonavir" /><entity charOffset="23-49" id="DDI-PubMed.23887590.s1.e1" text="(99m)Technetium-Mebrofenin" /><pair ddi="false" e1="DDI-PubMed.23887590.s1.e0" e2="DDI-PubMed.23887590.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23887590.s1.e0" e2="DDI-PubMed.23887590.s1.e1" /></sentence><sentence text="A semiphysiologically based pharmacokinetic (semi-PBPK) model was developed to describe a unique blood, liver, and bile clinical data set for the hepatobiliary imaging agent (99m)Technetium-mebrofenin ((99m)Tc-mebrofenin), and to simulate sites/mechanisms of a (99m)Tc-mebrofenin-ritonavir drug-drug interaction (DDI)"><entity charOffset="174-200" id="DDI-PubMed.23887590.s2.e0" text="(99m)Technetium-mebrofenin" /><entity charOffset="202-220" id="DDI-PubMed.23887590.s2.e1" text="(99m)Tc-mebrofenin" /><entity charOffset="261-289" id="DDI-PubMed.23887590.s2.e2" text="(99m)Tc-mebrofenin-ritonavir" /><pair ddi="false" e1="DDI-PubMed.23887590.s2.e0" e2="DDI-PubMed.23887590.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23887590.s2.e0" e2="DDI-PubMed.23887590.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23887590.s2.e0" e2="DDI-PubMed.23887590.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23887590.s2.e1" e2="DDI-PubMed.23887590.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23887590.s2.e1" e2="DDI-PubMed.23887590.s2.e2" /></sentence><sentence text=" The transport inhibitor ritonavir (multiple-dose: 2 × 300 mg) significantly increased systemic (99m)Tc-mebrofenin exposure as compared with control (4,464 ± 1,861 vs"><entity charOffset="25-34" id="DDI-PubMed.23887590.s3.e0" text="ritonavir" /><entity charOffset="96-114" id="DDI-PubMed.23887590.s3.e1" text="(99m)Tc-mebrofenin" /><pair ddi="false" e1="DDI-PubMed.23887590.s3.e0" e2="DDI-PubMed.23887590.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23887590.s3.e0" e2="DDI-PubMed.23887590.s3.e1" /></sentence><sentence text=" 1,970 ± 311 nCi min/ml; mean ± SD), without affecting overall hepatic exposure or biliary recovery" /><sentence text=" A novel extrahepatic distribution compartment was required to characterize (99m)Tc-mebrofenin disposition"><entity charOffset="76-94" id="DDI-PubMed.23887590.s5.e0" text="(99m)Tc-mebrofenin" /></sentence><sentence text=" Ritonavir inhibited (99m)Tc-mebrofenin accumulation in human sandwich-cultured hepatocytes (SCH) (half maximal inhibitory concentration (IC50) = 3"><entity charOffset="1-10" id="DDI-PubMed.23887590.s6.e0" text="Ritonavir" /></sentence><sentence text="46 ± 1" /><sentence text="53 µmol/l)" /><sentence text=" Despite ritonavir accumulation in hepatocytes, intracellular binding was extensive (97"><entity charOffset="9-18" id="DDI-PubMed.23887590.s9.e0" text="ritonavir" /></sentence><sentence text=" 6%), which limited interactions with multidrug resistance protein 2 (MRP2)-mediated biliary excretion" /><sentence text=" These in vitro data supported conclusions from modeling/simulation that ritonavir inhibited (99m)Tc-mebrofenin hepatic uptake, but not biliary excretion, at clinically relevant concentrations"><entity charOffset="73-82" id="DDI-PubMed.23887590.s11.e0" text="ritonavir" /></sentence><sentence text=" This integrated approach, utilizing modeling, clinical, and in vitro data, emphasizes the importance of hepatic and extrahepatic distribution, assessment of inhibitory potential in relevant in vitro systems, and intracellular unbound concentrations to assess transporter-mediated hepatic DDIs" /><sentence text="CPT: Pharmacometrics &amp; Systems Pharmacology (2013) 2, e20; doi:10" /><sentence text="1038/psp" /><sentence text="2012" /><sentence text="21; advance online publication 2 January 2013" /><sentence text=" " /></document>